Pacific Edge Limited
0.19
AUD
+0.01
(+2.70%)
ISIN
NZPEBE0002S1
Return %
Stock
S&P 500
1Y
15.15
14.20
3Y
106.52
81.12
5Y
-86.43
68.34
Capital Structure
NZD
•
in mil. unless spec.Working Capital
NZD
•
in mil. unless spec.Growth Rates
NZD
•
in mil. unless spec.Semi-annual Revenue
NZD
•
in mil. unless spec.Semi-annual Earnings Per Share
NZD
•
in mil. unless spec.Semi-annual Dividends Per Share
NZD
•
in mil. unless spec.Company Description
- CEO
- Peter Meintjes
- Full Time Employees
- 114
- Sector
- Health technology
- Industry
- Biotechnology
- Address
- Centre for Innovation Dunedin OT New Zealand 9016
- IPO Date
- Dec 2, 2002
- Website
- pacificedgedx.com
- Similar Companies
- Business
- Pacific Edge Limited (NZX: PEB), founded in 2001 and headquartered in Dunedin, New Zealand, specializes in the discovery, development, and commercialization of molecular diagnostic and prognostic tests for the early detection and management of bladder cancer; the company operates central laboratories in New Zealand and the United States, serving urologists and healthcare providers globally with non-invasive urine-based assays that utilize genetic and phenotypic biomarkers for superior accuracy over traditional cytology. Its core commercial portfolio comprises the Cxbladder suite of four proprietary tests—Cxbladder Detect, Triage, Monitor, and a suite addressing hematuria investigation, initial triage, post-treatment surveillance, and recurrence monitoring—validated through international multi-center clinical studies and included in the American Urological Association (AUA) guidelines for microhematuria evaluation; these products target unmet needs in urothelial cancer pathways, enabling faster clinical decisions, reduced cystoscopies, and improved patient outcomes in markets including North America, Europe, and Asia-Pacific. Pacific Edge segments its operations into Commercial (laboratory testing and sales worldwide) and Research (ongoing R&D in New Zealand and Australia), with approximately 114 employees supporting product innovation, regulatory compliance, and market access efforts. In recent developments, Pacific Edge launched a NZ$20 million capital raise in May 2025, comprising a NZ$15 million placement to institutional investors and a NZ$5 million share purchase plan for retail shareholders at NZ$0.10 per share, successfully securing NZ$16 million in the placement with oversubscriptions and closing the SPP with NZ$20.7 million total pledges by July 2025 to extend cash reserves beyond 12 months amid U.S. Medicare non-coverage for certain tests effective April 2025; proceeds fund accelerated Cxbladder Triage adoption leveraging AUA guideline inclusion, clinical evidence generation for enhanced Triage Plus and Monitor Plus variants, appeals for Medicare reconsideration, growth in non-Medicare U.S. channels, and development of in-vitro diagnostic (IVD) kits for decentralized international deployment. The company continues advancing its first-mover advantage in bladder cancer diagnostics, with directors and senior management participating in the equity raise and robust FY25 financials underscoring commercial momentum despite reimbursement challenges.
Company News
Pacific Edge Limited (PFGTF) Shareholder/Analyst Call Transcript
Pacific Edge Limited (PFGTF) Q4 2026 Earnings Call Transcript